+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oral Proteins & Peptides Market - Global Forecast 2026-2032- Product Image
Oral Proteins & Peptides Market - Global Forecast 2026-2032- Product Image
Sale

Oral Proteins & Peptides Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968731
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oral Proteins & Peptides Market is projected to reach USD 8.80 Billion in 2026. It is expected to continue growing at a CAGR of 13.29%, reaching USD 18.66 Billion by 2032.

The oral proteins and peptides market is moving from a long-standing formulation challenge into a strategic pharmaceutical growth arena. Protein and peptide therapeutics such as GLP-1 receptor agonists, insulin candidates, parathyroid hormone analogs, calcitonin, and somatostatin analogs have historically relied on injections because gastrointestinal enzymes, mucus barriers, and epithelial tight junctions restrict oral bioavailability.

Commercial progress has validated the category. The U.S. FDA approved oral semaglutide in 2019 as the first oral GLP-1 receptor agonist, and oral octreotide capsules were approved in 2020 for acromegaly maintenance therapy. These milestones support growing investment in permeation enhancers, enzyme inhibitors, enteric coatings, nanoparticles, mucoadhesive systems, and device-enabled capsules designed to improve absorption while preserving peptide stability.

Transformative Shifts in the Oral Peptide Delivery Landscape

The most important shift is the movement from proof-of-concept oral delivery toward differentiated product life-cycle strategies. Pharmaceutical developers are using oral peptide programs to improve patient adherence, extend therapeutic options, reduce injection burden, and compete in chronic diseases where convenience directly affects persistence.

Demand is being reinforced by the global burden of metabolic disease. The International Diabetes Federation estimated that 537 million adults were living with diabetes in 2021, while the World Health Organization reported that more than 1 billion people were living with obesity in 2022. These epidemiological realities make oral GLP-1 therapies, oral insulin approaches, and other peptide-based therapies high-priority targets for clinical development and commercialization.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating oral protein and peptide development by improving peptide design, excipient selection, stability prediction, and formulation screening. Machine learning models can evaluate relationships among molecular weight, charge, hydrophobicity, proteolytic susceptibility, permeability, and release kinetics, reducing the number of laboratory iterations required to identify promising candidates.

AI is also influencing clinical and commercial execution. Predictive analytics support patient stratification, dose optimization, adherence modeling, pharmacovigilance signal detection, and manufacturing process control. As regulatory agencies increasingly accept model-informed drug development when supported by robust evidence, AI-enabled workflows are becoming a competitive advantage rather than a peripheral research tool.

Key Regional Insights Across Global Markets

North America remains a leading region because of its concentration of biotechnology capabilities, advanced clinical trial infrastructure, strong payer engagement, and FDA experience with oral peptide approvals. The United States anchors demand through high diabetes and obesity prevalence, while Canada contributes through publicly supported research networks and an increasingly sophisticated specialty pharmaceutical environment.

Europe benefits from established regulatory pathways through the European Medicines Agency, strong biologics manufacturing capabilities, and active peptide research across Germany, France, Italy, Spain, and the United Kingdom. Asia-Pacific is gaining momentum as China, India, Japan, South Korea, and Australia expand clinical development capacity, contract manufacturing, and demand for chronic disease therapies. Latin America, led by Brazil and Mexico, shows rising access potential as metabolic disorders increase and private specialty channels develop, while the Middle East is shaped by high diabetes burden and healthcare modernization across Gulf health systems. Africa remains earlier in adoption but is increasingly relevant as urbanization, noncommunicable disease strategies, and medicine access initiatives expand across major economies.

Key Group Insights for Strategic Market Prioritization

ASEAN countries are becoming important for oral peptide market expansion as healthcare coverage improves and regional manufacturers strengthen formulation, packaging, and distribution capabilities. Singapore and Malaysia offer clinical and regulatory sophistication, while Indonesia, Thailand, Vietnam, and the Philippines provide sizable patient populations for diabetes and cardiometabolic therapies.

The GCC is increasingly relevant due to national diabetes management programs, specialty care investment, and healthcare transformation initiatives across Gulf economies. The European Union supports harmonized regulatory review, pharmacovigilance, and high-quality manufacturing standards that are important for complex oral biologics. BRICS countries offer scale, domestic manufacturing priorities, and rising demand for chronic disease treatment, particularly in China, India, and Brazil. G7 markets continue to lead premium innovation, clinical evidence generation, and reimbursement discussions, while NATO countries overlap heavily with advanced North American and European markets, supporting resilient supply chains, stringent quality expectations, and coordinated regulatory standards.

Key Country Insights for Oral Proteins and Peptides

The United States is the most influential country market due to FDA precedent, high specialty drug utilization, and a large population affected by obesity and diabetes. Canada offers stable market access pathways and research collaborations, while Mexico and Brazil provide important Latin American demand opportunities as private healthcare, specialist prescribing, and specialty pharmacy channels expand.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine clinical research depth with advanced reimbursement systems, while Russia remains a differentiated market shaped by localization requirements, regulatory complexity, and access constraints. China and India are central to future scale because of large patient populations, active domestic pharmaceutical investment, expanding clinical trial activity, and policy focus on local production. Japan and South Korea contribute advanced drug delivery research, strong quality systems, and high adoption of innovative therapies, while Australia serves as a credible clinical development and early market access environment supported by recognized regulatory standards and research infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize candidates where oral delivery provides measurable clinical and commercial value, including chronic diseases requiring long-term adherence. Programs should demonstrate not only bioavailability but also durable efficacy, acceptable food-effect management, gastrointestinal tolerability, and clear patient preference versus injectable alternatives.

Organizations should invest in platform technologies, AI-enabled formulation screening, scalable manufacturing, and early regulatory engagement. Commercial teams should prepare evidence packages for payers that quantify adherence, persistence, total cost of care, and quality-of-life benefits. Partnerships with contract development and manufacturing organizations, academic laboratories, and digital adherence providers can reduce development risk and accelerate launch readiness.

Research Methodology

This executive summary is developed using a structured secondary research methodology aligned with established market intelligence standards. Inputs include regulatory approval records, public agency publications, peer-reviewed literature, clinical trial registries, patent activity, and recognized epidemiological sources such as the International Diabetes Federation and the World Health Organization.

The analysis triangulates technology trends, therapeutic demand, regional healthcare infrastructure, regulatory maturity, and commercialization dynamics. Insights are validated through consistency checks across multiple sources and are presented without unsupported market sizing, market share claims, or speculative forecasting.

Conclusion

Oral proteins and peptides are positioned to reshape biologic therapy by combining the potency of peptide drugs with the convenience of oral administration. The market is supported by proven regulatory milestones, expanding metabolic disease demand, and rapid advances in formulation science.

The strongest performers will be organizations that integrate drug delivery innovation, AI-driven development, clinical differentiation, scalable manufacturing, and payer-relevant outcomes. As oral peptide platforms mature, they can improve adherence, expand access, and create new competitive benchmarks across chronic and specialty care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oral Proteins & Peptides Market, by Product Type
7.1. Introduction
7.2. Insulin-Based Proteins
7.2.1. Combination Insulin Products
7.2.2. Long-Acting Insulin Analogues
7.2.3. Rapid-Acting Insulin Analogues
7.2.4. Recombinant Human Insulin
7.3. Peptide Therapeutics
7.3.1. Calcitonin-Based Therapies
7.3.2. Glucagon-Like Peptide-1 Receptor Agonists
7.3.3. Vasopressin Analogs
8. Oral Proteins & Peptides Market, by Formulation
8.1. Introduction
8.2. Capsule Formulations
8.3. Liquid Formulations
8.4. Powder Formulations
8.5. Tablet Formulations
9. Oral Proteins & Peptides Market, by Patient Type
9.1. Introduction
9.2. Pediatric
9.3. Adult
9.4. Geriatric
10. Oral Proteins & Peptides Market, by Application
10.1. Introduction
10.2. Cancer Treatment
10.3. Cardiovascular Diseases
10.4. Diabetes Management
10.5. Hormonal Disorders
11. Oral Proteins & Peptides Market, by End-User
11.1. Introduction
11.2. Home Care Settings
11.3. Hospitals & Clinics
11.4. Research Laboratories
11.5. Specialty Clinics
12. Oral Proteins & Peptides Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. Oral Proteins & Peptides Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Oral Proteins & Peptides Market, by Group
14.1. NATO
14.2. G7
14.3. European Union
14.4. BRICS
14.5. ASEAN
14.6. GCC
15. Oral Proteins & Peptides Market, by Country
15.1. United States
15.2. China
15.3. Germany
15.4. Japan
15.5. India
15.6. United Kingdom
15.7. France
15.8. Canada
15.9. Italy
15.10. Australia
15.11. South Korea
15.12. Brazil
15.13. Mexico
15.14. Russia
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Amgen Inc.
17.3. Amryt Pharma plc
17.4. Astellas Pharma Inc.
17.5. AstraZeneca PLC
17.6. Biocon Limited
17.7. Boehringer Ingelheim International GmbH
17.8. Catalent, Inc.
17.9. Entera Bio Ltd. by DNA Biomedical Solutions
17.10. F. Hoffmann-La Roche AG
17.11. Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
17.12. Johnson & Johnson Services, Inc.
17.13. Merck KGaA
17.14. Novartis AG
17.15. Novo Nordisk A/S
17.16. Oramed Pharmaceuticals Inc.
17.17. PeptiDream Inc.
17.18. Pfizer, Inc.
17.19. Protagonist Therapeutics, Inc.
17.20. Proxima Concepts Limited
17.21. Rani Therapeutics, LLC
17.22. Sanofi S.A.
17.23. Tarsa Therapeutics, Inc.
17.24. Teva Pharmaceutical Industries Ltd.
17.25. Zealand Pharma A/S
List of Figures
FIGURE 1. GLOBAL ORAL PROTEINS & PEPTIDES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ORAL PROTEINS & PEPTIDES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INSULIN-BASED PROTEINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INSULIN-BASED PROTEINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INSULIN-BASED PROTEINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL COMBINATION INSULIN PRODUCTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL COMBINATION INSULIN PRODUCTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL COMBINATION INSULIN PRODUCTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL LONG-ACTING INSULIN ANALOGUES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL LONG-ACTING INSULIN ANALOGUES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL LONG-ACTING INSULIN ANALOGUES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL RAPID-ACTING INSULIN ANALOGUES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL RAPID-ACTING INSULIN ANALOGUES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL RAPID-ACTING INSULIN ANALOGUES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL RECOMBINANT HUMAN INSULIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL RECOMBINANT HUMAN INSULIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL RECOMBINANT HUMAN INSULIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL CALCITONIN-BASED THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL CALCITONIN-BASED THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CALCITONIN-BASED THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL VASOPRESSIN ANALOGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL VASOPRESSIN ANALOGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL VASOPRESSIN ANALOGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CAPSULE FORMULATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CAPSULE FORMULATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CAPSULE FORMULATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL LIQUID FORMULATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL LIQUID FORMULATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL LIQUID FORMULATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL POWDER FORMULATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL POWDER FORMULATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL POWDER FORMULATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL TABLET FORMULATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL TABLET FORMULATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL TABLET FORMULATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CANCER TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL CANCER TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL DIABETES MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL DIABETES MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL DIABETES MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HORMONAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL HORMONAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL HORMONAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 97. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 99. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 100. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 101. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 102. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 103. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 104. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 105. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 124. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 126. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 127. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 128. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 129. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 130. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 131. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 132. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 143. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 145. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 146. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 147. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 148. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 149. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 150. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 151. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 152. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 153. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 154. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 155. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 156. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 157. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 158. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 159. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 160. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 170. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 171. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 172. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 173. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 174. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 175. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 176. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 177. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 178. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 179. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 180. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 181. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 182. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 183. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 184. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 185. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 186. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 187. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 188. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 189. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 190. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 191. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 192. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 193. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 194. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 195. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 196. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 197. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 198. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 199. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 200. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 201. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 202. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 203. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 204. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 205. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 206. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 207. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 208. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 209. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 210. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 211. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 212. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 213. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 214. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 215. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 216. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 217. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 218. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 219. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 220. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 221. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 222. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 223. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 224. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 225. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 226. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 227. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 228. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 229. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 230. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 231. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 232. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 233. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 234. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 235. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 236. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 237. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 238. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 239. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 240. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 241. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 242. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 243. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 244. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 245. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 250. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 251. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 252. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 253. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 254. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 255. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 256. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 257. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 258. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 259. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 260. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 261. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 262. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 263. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 264. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 265. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 266. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 267. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 268. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 269. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 270. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 272. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 273. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 274. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 275. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 276. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 277. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 278. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 279. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 281. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 282. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 283. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 284. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 285. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 286. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 287. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 288. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 289. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 290. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 291. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 292. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 293. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 294. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 295. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 296. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 297. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 298. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 299. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 300. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 301. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 302. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 303. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 304. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 305. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 306. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 307. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 308. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 309. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 310. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 311. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 312. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 313. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 314. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 315. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 316. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 317. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 318. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 319. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 320. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 321. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 322. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 323. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 324. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 326. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2017-2032 (USD MILLION)
TABLE 327. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 328. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 329. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 330. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 331. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 332. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 333. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2025
TABLE 334. GLOBAL ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Amryt Pharma plc
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Entera Bio Ltd. by DNA Biomedical Solutions
  • F. Hoffmann-La Roche AG
  • Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • PeptiDream Inc.
  • Pfizer, Inc.
  • Protagonist Therapeutics, Inc.
  • Proxima Concepts Limited
  • Rani Therapeutics, LLC
  • Sanofi S.A.
  • Tarsa Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zealand Pharma A/S

Table Information

Report AttributeDetails
No. of Pages181
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 8.8 Billion
Forecasted Market Value ( USD ) by 2032 $ 18.66 Billion
Compound Annual Growth Rate13.2%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Oral Proteins and Peptides Market Size, Share, Trends, and Forecast by Drug Type, Applications, and Region, 2026-2034 - Product Image

Oral Proteins and Peptides Market Size, Share, Trends, and Forecast by Drug Type, Applications, and Region, 2026-2034

  • Report
  • 139 Pages
  • Global
From
Oral Proteins and Peptides Market Outlook 2026-2034: Market Share, and Growth Analysis by Product Type, Application, End-User, Formulation - Product Image

Oral Proteins and Peptides Market Outlook 2026-2034: Market Share, and Growth Analysis by Product Type, Application, End-User, Formulation

  • Report
  • 160 Pages
  • Global
From
Oral Proteins and Peptides Market Report 2026 - Product Image

Oral Proteins and Peptides Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Oral Protein and Peptide Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Oral Protein and Peptide Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 192 Pages
  • Global
From
Oral Proteins and Peptides Market - Global Strategic Business Report - Product Image

Oral Proteins and Peptides Market - Global Strategic Business Report

  • Report
  • 278 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.